The effect of thalidomide on inflammtory lesions in a murine model of experimental colitis (CROSBI ID 479630)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Banić, Marko ; Pleško, Sanja ; Dohoczky, Cs. Anić, Branimir ; Brkić, Tomislav ; Ferenčić, Željko ; Gomerčić, Vera ; Rotkvić, Ivo ;
engleski
The effect of thalidomide on inflammtory lesions in a murine model of experimental colitis
Experimental and clinical studies have documented the effect of thalidomide in numerous and immunologicaly mediated diseases and conditions, including chronic intestinal form of GVHD. The aim of the study was to determine the effect of thalidomide in murin model of experimental colitis. Experimental colitis was induced in NMRI mice (PLIVA Research Institute) using the enema of 0.2 percent solution of Dinitrofluorobenzen (DFNB) (Sigm, Saint Louis, USA) in 4:1 acetone to olive oil solution, and combined with previous skin sensitisation. Experimental groups of animals were treated with Cyclosporine A (CsA)(3 mg/kg/day), methylperdnisolone (10mg/kg/day) and thalidomide (10 mg/kg (day) interperitoneale (i.p.), starting 6 hours after induction of colitis and for 5 consecutive days. Control groups treated with phosphate buffered saline (PBS) in the same manner after induction of colitis. On day 5, all the animals were killed and entire colons were taken for histology. Colonic lesions were assessed using a histopathologic score ranging 0-30. CsA and methilprednosolone were proven to be effective in diminishing the extent of provoked colonic inflammation (Mann-Whitney, p less than 0.05). In experimental group treated with thalidomide the inflammatory lesions were also less expressed but there was no significant difference, when compared to control group with maximal observed lesions (p less than 0.07, Mann-Whitney). In spite of the fact that thalidomide was proven to be effective immunosupressant, in this particular model of experimental colitis it may not have the anti-inflammatory effect in the range of methylpredonisolone and CsA.
colonic inflammatory disease; thalidomide
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
66-66.
1999.
objavljeno
Podaci o matičnoj publikaciji
Abstract book of the Falk symposium No 111 : IBD at the End of its First Century
Scholmerich, J.
Freiburg: Falk Foundation e. V.
Podaci o skupu
Nepoznat skup
poster
29.02.1904-29.02.2096